News >

Avapritinib Approval Sought in Taiwan for PDGFRA Exon 18+ GIST

Jason M. Broderick @jasoncology
Published: Friday, Mar 27, 2020

Frank Jiang, MD, PhD

Frank Jiang, MD, PhD

A new drug application has been submitted to the Taiwan Food and Drug Administration for avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring PDGFRA exon 18 mutations, including PDGFRA D842V mutations, according to CStone Pharmaceuticals, a partner of Blueprint Medicines.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication